Education
About Us
Working with TipRanks
Follow Us
ENDRA Life Sciences Inc (NDRA)
NASDAQ:NDRA
NDRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.15 - $698.25
Previous CloseN/A
Volume13.45K
Average Volume (3M)8.65K
Market Cap
$2.20M
Enterprise Value$715.98K
Total Cash (Recent Filing)-$156.44K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.03
Next Earnings
May 19, 2025EPS Estimate
-4.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-934.10
Shares Outstanding562,213
10 Day Avg. Volume6,060
30 Day Avg. Volume8,654
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.60
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$75.00Price Target Upside1733.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
ENDRA Life Sciences News
PremiumCompany Announcements
ENDRA Life Sciences Advances TAEUS Liver Device Strategy
PremiumCompany Announcements
ENDRA Life Sciences Reports Q3 2024 Results and Progress
PremiumPre-Earnings
Is NDRA a Buy, Before Earnings?
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company has $5 million in cash and no debt, believed to be enough cash into mid-2025.
LeadershipENDRA appointed Alexander Tokman as acting CEO, a growth-driven executive with 24+ years of experience in the development and commercialization of new technology products and services.
Market PotentialMaintaining a BUY rating, with a significant upside potential suggested by a 12-month price target of $75, balancing high risks with high growth prospects and large upside opportunities.
Bears Say
Product CommercializationIn March 2020, ENDRA received CE Mark approval, and is now starting initial commercialization activity in Europe.
Revenue GenerationENDRA is a late stage medical device development/early stage commercialization company so it generates no revenues.
---
Ownership Overview
27.19% Insiders
0.01% Mutual Funds
― Other Institutional Investors
72.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NDRA FAQ
What was ENDRA Life Sciences Inc’s price range in the past 12 months?
ENDRA Life Sciences Inc lowest stock price was $3.15 and its highest was $698.25 in the past 12 months.
What is ENDRA Life Sciences Inc’s market cap?
ENDRA Life Sciences Inc’s market cap is $2.20M.
When is ENDRA Life Sciences Inc’s upcoming earnings report date?
ENDRA Life Sciences Inc’s upcoming earnings report date is May 19, 2025 which is in 46 days.
How were ENDRA Life Sciences Inc’s earnings last quarter?
ENDRA Life Sciences Inc released its earnings results on Mar 31, 2025. The company reported -$47.06 earnings per share for the quarter, missing the consensus estimate of -$4.1 by -$42.96.
Is ENDRA Life Sciences Inc overvalued?
According to Wall Street analysts ENDRA Life Sciences Inc’s price is currently Undervalued.
Does ENDRA Life Sciences Inc pay dividends?
ENDRA Life Sciences Inc does not currently pay dividends.
What is ENDRA Life Sciences Inc’s EPS estimate?
ENDRA Life Sciences Inc’s EPS estimate is -4.1.
How many shares outstanding does ENDRA Life Sciences Inc have?
ENDRA Life Sciences Inc has 562,213 shares outstanding.
What happened to ENDRA Life Sciences Inc’s price movement after its last earnings report?
ENDRA Life Sciences Inc reported an EPS of -$47.06 in its last earnings report, missing expectations of -$4.1. Following the earnings report the stock price went up 1.235%.
Which hedge fund is a major shareholder of ENDRA Life Sciences Inc?
Currently, no hedge funds are holding shares in NDRA
---
Company Description
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
---
NDRA Stock 12 Month Forecast
Average Price Target
$75.00
▲(1733.74% Upside)
Technical Analysis
Best Analysts Covering NDRA
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-78.77%
reiterated a buy rating 4 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -78.77% per trade.
---